The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus

Ünlü, Ozan; Zuily, Stéphane; Erkan, Doruk

doi:10.5152/eurjrheum.2015.0085

Cited by 172 publications

(88 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the impact of aPL on SLE is well studied (5, 7), limited data exist regarding the impact of SLE on the clinical phenotype of persistently aPL-positive patients. In a European multicenter cohort of 1,000 mainly Caucasian patients with APS, patients with concomitant SLE had higher prevalence of livedo reticularis, thrombocytopenia, arthritis, and leukopenia (13).…”

Section: Discussionmentioning

confidence: 99%

“…(4). Thirty-to-forty percent of SLE patients are positive for aPL (5); the prevalence of a “clinically significant” aPL profile (positive LA test based on the guidelines of International Society of Thrombosis and Haemostasis [ISTH] (6), aCL IgG/IgM greater than or equal to 40 GPL/MPL, and/or aβ 2 GPI IgG/IgM greater than or equal to 40 GPL/MPL, tested twice at least 12 weeks apart) is approximately 30% (7). Although aPL-positivity has an impact on the clinical presentation and prognosis of SLE patients (5), there are limited number of studies analyzing the impact of SLE on the clinical phenotype and prognosis of aPL-positive patients (8).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody–Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository

Ünlü

Erkan

Barbhaiya

et al. 2018

Arthritis Care & Research

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody–Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository

Ünlü

Erkan

Barbhaiya

et al. 2018

Arthritis Care & Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…According to relevant literature, pregnancy and delivery are the causes of SLE deterioration. Some scholars believed that about 50% of pregnant patients with SLE suffer from exacerbation and experience poor pregnancy and fetus outcomes [6]. This finding is mainly related to changes in hormonal levels during pregnancy.…”

Section: Discussionmentioning

confidence: 99%

Feasibility of hydroxychloroquine adjuvant therapy in pregnant women with systemic lupus erythematosus

Liu¹,

Liu²,

Zhou³

2018

biomedicalresearch

View full text Add to dashboard Cite

Objective: This study aims to investigate the clinical effects of hydroxychloroquine adjuvant therapy in pregnant women with Systemic Lupus Erythematosus (SLE). Methods: A total of 78 pregnant women with SLE from February 2016 to August 2017 were recruited and divided into two groups, control (n=39) and observation (n=39), by using a random number table. The observation group received hydroxychloroquine adjuvant therapy, whereas the control group received conventional symptomatic treatment. The lupus activity during pregnancy, term birth rate, pregnancy and fetus outcomes, new-born Apgar score, and neonatal weight of the two groups were compared. Results: The occurrence rate of lupus during pregnancy in the observation group was 25.64%, which was significantly lower than that of the control group (51.28%) (P<0.05). The observation group achieved significantly higher term birth rate (84.62%) than the control group (58.97%) (P<0.05). The occurrence rates of bad pregnancy and fetus outcomes of the observation and control groups were 17.95% and 44.44%, respectively, which showed a significant difference (P<0.05). The new-born Apgar score and neonatal weight of the observation group were 9.61 ± 0.25 and 2.78 ± 0.56 kg, whereas those of the control group were 8.10 ± 0.31 and 2.47 ± 0.58 kg, showing a significant difference (P<0.05). Conclusions: Hydroxychloroquine adjuvant therapy exerts outstanding clinical effects to pregnant patients with SLE. This therapy not only improves pregnancy outcome but also reduces the occurrence of lupus. This method has a very high clinical application value and is worthy of further clinical research and applications.

show abstract

“…In this study, a high-throughput peptide array was used for the first time to detect the binding epitopes of SLE-related autoantibodies. SLE-related autoantigens have been reported in many studies [ 29 , 30 ], and whole autoantigens can be used to detect autoantibodies. However, the complete expression of humanized antigens is very difficult; thus, using complete antigens for high-throughput screening is impossible.…”

Section: Discussionmentioning

confidence: 99%

Screening epitopes on systemic lupus erythematosus autoantigens with a peptide array

et al. 2017

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a common autoimmune disease. Many autoantibodies are closely associated with SLE. However, the specific epitopes recognized and bound by these autoantibodies are still unclear. This study screened the binding epitopes of SLE-related autoantibodies using a high-throughput screening method. Epitope prediction on 12 SLE-related autoantigens was performed using the Immune Epitope Database and Analysis Resource (IEDB) software. The predicted epitopes were synthesized into peptides and developed into a peptide array. Serum IgG from 50 SLE patients and 25 healthy controls was detected using the peptide array. The results were then validated using an enzyme-linked immunosorbent assay (ELISA). The diagnostic efficiency of each epitope was analyzed using a ROC curve. Seventy-three potential epitopes were screened for using the IEDB software after the epitopes on the 12 SLE-related autoantigens were analyzed. Peptide array screening revealed that the levels of the autoantibodies recognized and bound by 4 peptide antigens were significantly upregulated in the serum of SLE patients (P < 0.05). The ELISA results showed that the 4 antigens with significantly increased serum autoantibodies levels in SLE patients were acidic ribosomal phosphoprotein (P0)-4, acidic ribosomal phosphoprotein (P0)-11, DNA topoisomerase 1 (full length)-1, and U1-SnRNP 68/70 KDa-1 (P < 0.05), and the areas under the ROC curve for diagnosing SLE on the basis of these peptides were 0.91, 0.90, 0.93, and 0.91, respectively. Many autoantibodies specifically expressed in the serum of patients with SLE can be detected by specific peptide fragments and may be used as markers in clinical auxiliary diagnoses.

show abstract

The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus

Cited by 172 publications

References 141 publications

The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody–Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository

The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody–Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository

Feasibility of hydroxychloroquine adjuvant therapy in pregnant women with systemic lupus erythematosus

Screening epitopes on systemic lupus erythematosus autoantigens with a peptide array

Contact Info

Product

Resources

About